Detalhe da pesquisa
1.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med;
377(19): 1824-1835, 2017 11 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28891423
2.
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Gastric Cancer;
23(4): 689-698, 2020 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32128634
3.
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
Qual Life Res;
28(1): 109-119, 2019 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30191365
4.
Societal preferences for adjuvant melanoma health states: UK and Australia.
BMC Cancer;
17(1): 689, 2017 Oct 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29041898
5.
Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
Immunotherapy;
10(14): 1241-1252, 2018 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30175642
6.
Health-related quality of life results from the phase III CheckMate 067 study.
Eur J Cancer;
82: 80-91, 2017 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28651159
7.
The economic burden of posttransplant events in renal transplant recipients in Europe.
Transplantation;
97(8): 854-61, 2014 Apr 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24732898